Market Need Target the SBS market with cost-of-care data and payer considerations, highlighting the potential to reduce the current average 5-year cost per patient of $1.6M by offering a regenerative therapy that bypasses expensive medications and surgeries.

Clinical Reach Leverage partnerships with global SBS clinical thought leaders to accelerate validation, publishing and case studies that can support early adopter programs and clinician-led referrals.

Tech & Platform Position Eclipse XL1 as a high-value medical device with a supportive tech stack and scalable service model; emphasize regulatory readiness, clinical efficacy, and potential integration with hospital procurement and service vendors.

Funding & Revenue Pursue strategic financing and partnerships that can scale revenue toward multi-pocket payer coverage, leveraging the current revenue range of $1M–$10M to attract investors looking for high-need, high-impact therapies.

Expansion Signals Identify opportunities with large SBS patient populations and academic medical centers in the U.S. and internationally, focusing on pilot deployments, clinical trials, and reimbursement demonstrations to drive adoption.